NASDAQ:ELYM Eliem Therapeutics (ELYM) Stock Forecast, Price & News $2.63 +0.01 (+0.38%) (As of 09/29/2023 08:52 PM ET) Add Compare Share Share Today's Range$2.60▼$2.7350-Day Range$2.59▼$2.9052-Week Range$2.21▼$4.75Volume22,900 shsAverage Volume20,630 shsMarket Capitalization$71.25 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Eliem Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside128.1% Upside$6.00 Price TargetShort InterestHealthy0.21% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.42Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.21 out of 5 starsMedical Sector410th out of 970 stocksPharmaceutical Preparations Industry174th out of 443 stocks 3.0 Analyst's Opinion Consensus RatingEliem Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Eliem Therapeutics has a forecasted upside of 128.1% from its current price of $2.63.Amount of Analyst CoverageEliem Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.21% of the float of Eliem Therapeutics has been sold short.Short Interest Ratio / Days to CoverEliem Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eliem Therapeutics has recently decreased by 14.06%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEliem Therapeutics does not currently pay a dividend.Dividend GrowthEliem Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELYM. Previous Next 3.0 News and Social Media Coverage News SentimentEliem Therapeutics has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eliem Therapeutics this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eliem Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of Eliem Therapeutics is held by insiders.Percentage Held by Institutions61.78% of the stock of Eliem Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Eliem Therapeutics is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eliem Therapeutics is -1.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEliem Therapeutics has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Eliem Therapeutics (NASDAQ:ELYM) StockEliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial. The company was incorporated in 2018 and is headquartered in Redmond, Washington.Read More ELYM Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELYM Stock News HeadlinesSeptember 28, 2023 | finance.yahoo.comEliem Therapeutics (NASDAQ:ELYM) Is In A Good Position To Deliver On Growth PlansJuly 21, 2023 | finance.yahoo.comEliem (ELYM) to Explore Strategic Options, Stock Rises 6%October 2, 2023 | Legacy Research (Ad)Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”July 21, 2023 | msn.comEliem Therapeutics’ stock soars 21% premarket after company says it may sell itselfJuly 20, 2023 | benzinga.comWhat's Happening With Eliem Therapeutics Shares Today?July 20, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Announces Plans to Explore Strategic AlternativesJuly 20, 2023 | marketwatch.comEliem Therapeutics Shares Rally Premarket on Exploration of Options >ELYMJuly 20, 2023 | markets.businessinsider.comWhy Is Eliem Therapeutics (ELYM) Stock Up 6% Today?October 2, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...July 20, 2023 | finance.yahoo.comEliem Therapeutics Announces Plans to Explore Strategic AlternativesJune 7, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for Eliem Therapeutics (ELYM)May 25, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on Eliem Therapeutics (ELYM)May 12, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Reports First Quarter Financial Results and Business HighlightsMay 11, 2023 | seekingalpha.comEliem Therapeutics GAAP EPS of -$0.84May 11, 2023 | finance.yahoo.comEliem Therapeutics Reports First Quarter Financial Results and Business HighlightsApril 21, 2023 | finance.yahoo.comWe're Hopeful That Eliem Therapeutics (NASDAQ:ELYM) Will Use Its Cash WiselyMarch 9, 2023 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Eliem Therapeutics (ELYM)March 7, 2023 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business HighlightsMarch 6, 2023 | finance.yahoo.comEliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business HighlightsFebruary 23, 2023 | seekingalpha.comELYM Eliem Therapeutics, Inc.February 23, 2023 | finance.yahoo.comEliem Therapeutics slashing staff amid leadership shakeupFebruary 18, 2023 | finance.yahoo.comEliem Pauses Development On Depression Drug, Lays Off 55% WorkforceFebruary 10, 2023 | msn.comEliem Therapeutics down after announcing reprioritization plans, layoffsFebruary 9, 2023 | finance.yahoo.comEliem Therapeutics Provides Strategic Update and Announces Leadership TransitionNovember 30, 2022 | finance.yahoo.comEliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual ConferenceNovember 14, 2022 | finanznachrichten.deEliem Therapeutics, Inc.: Eliem Therapeutics Reports Third Quarter Financial and Business HighlightsNovember 12, 2022 | finance.yahoo.comIs Eliem Therapeutics (NASDAQ:ELYM) In A Good Position To Invest In Growth?See More Headlines Receive ELYM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eliem Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ELYM Company Calendar Last Earnings8/10/2023Today10/01/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ELYM CUSIPN/A CIK1768446 Webwww.eliemtx.com Phone877-354-3689FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+128.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-45,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-36.52% Return on Assets-34.97% Debt Debt-to-Equity RatioN/A Current Ratio31.58 Quick Ratio31.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.84 per share Price / Book0.54Miscellaneous Outstanding Shares27,090,000Free Float25,816,000Market Cap$71.25 million OptionableNot Optionable Beta0.47 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Andrew Levin M.D. (Age 46)Ph.D., Principal Financial Officer & Exec. Chairman Comp: $73kDr. Valerie Morisset Ph.D. (Age 53)Chief Scientific Officer and Exec. VP of R&D Comp: $617.87kMs. Emily Pimblett (Age 39)Principal Accounting Officer Ms. Jo Palmer-Phillips Ph.D.Chief Devel. OfficerDr. Mark Versavel M.B.A. (Age 64)M.D., MBA, Ph.D., Sr. VP & Chief Medical Officer Key CompetitorsHCW BiologicsNASDAQ:HCWBIncannex HealthcareNASDAQ:IXHLSCYNEXISNASDAQ:SCYXCorvus PharmaceuticalsNASDAQ:CRVSVeruNASDAQ:VERUView All CompetitorsInstitutional OwnershipSilverarc Capital Management LLCBought 8,134 shares on 8/15/2023Ownership: 1.830%Driehaus Capital Management LLCBought 136,909 shares on 8/14/2023Ownership: 3.003%Two Sigma Securities LLCBought 14,279 shares on 8/14/2023Ownership: 0.053%BML Capital Management LLCSold 75,000 shares on 7/24/2023Ownership: 5.866%View All Institutional Transactions ELYM Stock - Frequently Asked Questions Should I buy or sell Eliem Therapeutics stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eliem Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ELYM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ELYM, but not buy additional shares or sell existing shares. View ELYM analyst ratings or view top-rated stocks. What is Eliem Therapeutics' stock price forecast for 2023? 1 Wall Street research analysts have issued 1-year price objectives for Eliem Therapeutics' shares. Their ELYM share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 128.1% from the stock's current price. View analysts price targets for ELYM or view top-rated stocks among Wall Street analysts. How have ELYM shares performed in 2023? Eliem Therapeutics' stock was trading at $3.67 on January 1st, 2023. Since then, ELYM shares have decreased by 28.3% and is now trading at $2.63. View the best growth stocks for 2023 here. Are investors shorting Eliem Therapeutics? Eliem Therapeutics saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 37,300 shares, a drop of 14.1% from the August 31st total of 43,400 shares. Based on an average trading volume of 33,600 shares, the days-to-cover ratio is currently 1.1 days. Currently, 0.2% of the company's stock are sold short. View Eliem Therapeutics' Short Interest. When is Eliem Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our ELYM earnings forecast. How were Eliem Therapeutics' earnings last quarter? Eliem Therapeutics, Inc. (NASDAQ:ELYM) posted its earnings results on Thursday, August, 10th. The company reported ($0.19) EPS for the quarter. When did Eliem Therapeutics IPO? (ELYM) raised $75 million in an initial public offering on Tuesday, August 10th 2021. The company issued 6,000,000 shares at a price of $12.50 per share. SVB Leerink, Evercore ISI, Stifel and Guggenheim Securities served as the underwriters for the IPO. What is Eliem Therapeutics' stock symbol? Eliem Therapeutics trades on the NASDAQ under the ticker symbol "ELYM." How do I buy shares of Eliem Therapeutics? Shares of ELYM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Eliem Therapeutics' stock price today? One share of ELYM stock can currently be purchased for approximately $2.63. How much money does Eliem Therapeutics make? Eliem Therapeutics (NASDAQ:ELYM) has a market capitalization of $71.25 million. The company earns $-45,240,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis. How can I contact Eliem Therapeutics? The official website for the company is www.eliemtx.com. The company can be reached via phone at 877-354-3689 or via email at investorrelations@eliemtx.com. This page (NASDAQ:ELYM) was last updated on 10/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.